| Constance L Jones, LCSW | |
|
781 College Street, Macon, GA 31201 | |
| (478) 742-2953 | |
| (478) 742-2953 |
| Full Name | Constance L Jones |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 781 College Street, Macon, Georgia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144393554 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | MFT000530 (Georgia) | Secondary |
| 1041C0700X | Social Worker - Clinical | CSW000891 (Georgia) | Primary |
| Entity Name | Warren Jones Lmft. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871151050 PECOS PAC ID: 9234509241 Enrollment ID: O20230109002933 |
News Archive
Helicobater pylori, a bacteria implicated in peptic ulcers and gastritis, was eradicated in 95 percent patients who took a 7-day course of combination therapy with levofloxacin, omeprazole, nitazoxanide (Alinia®) and doxycycline (LOAD) compared to eradication in only 80.9 percent of patients on lansoprazole, amoxicillin and clarithromycin (LAC) for seven days.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 1 study of PV-10 for liver cancer. The study will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. PV-10 is the company's lead oncology drug candidate that is also currently undergoing Phase 2 study for metastatic melanoma.
In a recent study, a Yale Cancer Center team revealed that the addition of chemotherapy to postoperative treatment for adults with medulloblastoma improves survival.
BioTrends Research Group, Inc. released Wave 2 of its LaunchTrends(TM): Feraheme report, the second in a multi-phase syndicated market research project tracking the launch of AMAG's new IV iron product, Feraheme, through the first six months of product availability. Each wave of the report provides quantitative information from 50 unique Nephrologists and qualitative information from a subset of 15.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Constance L Jones, LCSW 781 College Street, Macon, GA 31201 Ph: (478) 742-2953 | Constance L Jones, LCSW 781 College Street, Macon, GA 31201 Ph: (478) 742-2953 |
News Archive
Helicobater pylori, a bacteria implicated in peptic ulcers and gastritis, was eradicated in 95 percent patients who took a 7-day course of combination therapy with levofloxacin, omeprazole, nitazoxanide (Alinia®) and doxycycline (LOAD) compared to eradication in only 80.9 percent of patients on lansoprazole, amoxicillin and clarithromycin (LAC) for seven days.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 1 study of PV-10 for liver cancer. The study will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. PV-10 is the company's lead oncology drug candidate that is also currently undergoing Phase 2 study for metastatic melanoma.
In a recent study, a Yale Cancer Center team revealed that the addition of chemotherapy to postoperative treatment for adults with medulloblastoma improves survival.
BioTrends Research Group, Inc. released Wave 2 of its LaunchTrends(TM): Feraheme report, the second in a multi-phase syndicated market research project tracking the launch of AMAG's new IV iron product, Feraheme, through the first six months of product availability. Each wave of the report provides quantitative information from 50 unique Nephrologists and qualitative information from a subset of 15.
› Verified 3 days ago